Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
Status:
Completed
Trial end date:
2012-10-09
Target enrollment:
Participant gender:
Summary
The objective was to determine the effects of a single dose of migalastat hydrochloride (HCl)
(migalastat) 150 and 450 milligrams (mg) on the safety and plasma pharmacokinetics (PK) of
agalsidase and the effects of agalsidase on the safety and PK of migalastat 150 mg.